Employees: 413
Size Beijing Scitop Bio-Tech (300858.SZ) is a China Health Care company (Biotechnology) with a market value of $501M, the 3696th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.66 on 18 Nov 2026.
Performance Over six months the shares fell 28.3%, against -5.6% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 18 in its peer set.
Growth Revenue grew 3.9% over the last twelve months (peer median -6.5%); the operating margin is 7.8% (peer median -13.1%).
Valuation It trades at 21.5× forward earnings against a peer median of 17.9× (3rd most expensive of 6).
Capital Return on invested capital runs 3.2 points below its cost of capital (6.9% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥365M | CN¥363M | CN¥300M | CN¥297M | CN¥367M |
| Revenue growth | — | +21% | +1% | -19% | — |
| Gross profit | CN¥189M | CN¥176M | CN¥165M | CN¥152M | CN¥183M |
| EBITDA | n/a | CN¥108M | CN¥97.4M | CN¥85.1M | CN¥127M |
| Net income | CN¥54.0M | CN¥94.5M | CN¥94.4M | CN¥93.5M | CN¥110M |
| Free cash flow | -CN¥28.0M | -CN¥173M | -CN¥69.4M | -CN¥71.2M | CN¥64.3M |
| Capital expenditure | CN¥110M | CN¥296M | CN¥211M | CN¥178M | CN¥84.2M |
| Total debt | CN¥3.54M | CN¥3.59M | CN¥3.79M | CN¥11.7M | CN¥7.70M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300858.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.0% | -12.1% | 10th highest of 21 |
| 6-month return | -28.3% | -5.6% | 3rd lowest of 18 |
| Distance from 52-week high | -53.2% | -44.6% | 5th lowest of 21 |
| Revenue growth (TTM) | +3.9% | -6.5% | 6th highest of 14 |
| Operating margin | 7.8% | -13.1% | 3rd highest of 14 |
| Forward P/E | 21.5× | 17.9× | 3rd most expensive of 6 |
| ROIC minus cost of capital | -3.2 pp | -5.5 pp | 3rd highest of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Scitop Bio-Tech 300858.SZ | China | $501M | -28% | +4% | 8% | 21.5× | n/a | n/a |
| Valneva VLA.PA | France | $508M | -6% | -27% | -87% | n/a | n/a | n/a |
| Sinotherapeutics 688247.SS | China | $494M | -19% | -17% | 0% | n/a | 29.4% | +7.0% |
| LongBio Pharma (Suzhou) 1779.HK | Hong Kong | $510M | n/a | n/a | n/a | n/a | n/a | n/a |
| Liaoning Dingjide Petrochemical 603255.SS | China | $490M | -24% | +70% | 5% | 37.5× | n/a | n/a |
| CHO Pharma 6586.TWO | Taiwan | $488M | +24% | -47% | -17,694% | n/a | n/a | n/a |
| Beijing Bohui Innovation Biotechnology 300318.SZ | China | $518M | -20% | -1% | -13% | n/a | n/a | n/a |
| Crescent Biopharma CBIO | United States | $482M | -34% | n/a | -1,217% | n/a | n/a | n/a |
| TaiMed Biologics 4147.TWO | Taiwan | $480M | +19% | +7% | -31% | n/a | n/a | n/a |
| Monopar Therapeutics MNPR | United States | $479M | +9% | n/a | n/a | n/a | n/a | n/a |
| Neurogene NGNE | United States | $479M | -14% | -100% | n/a | n/a | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $471M | +37% | +71% | 5% | 16.9× | 58.8% | +204.7% |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $470M | n/a | n/a | n/a | n/a | n/a | n/a |
| Kamada KMDA | United States | $465M | +3% | +5% | 15% | 17.9× | 5.0% | +6.5% |
| Frontage 1521.HK | Hong Kong | $542M | +113% | +10% | 8% | 24.6× | 14.3% | +15.4% |
| DiaMedica Therapeutics DMAC | United States | $463M | +50% | n/a | n/a | n/a | n/a | n/a |
| HanchorBio 7827.TW | Taiwan | $462M | n/a | n/a | -4,673% | 2.3× | n/a | n/a |
| Climb Bio CLYM | United States | $546M | -12% | n/a | n/a | n/a | n/a | n/a |
| Wave Life Sciences WVE | United States | $546M | -55% | -35% | -321% | n/a | n/a | n/a |
| Shattuck Labs STTK | United States | $455M | -28% | -100% | n/a | n/a | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $454M | -2% | -6% | -1% | n/a | n/a | n/a |